Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$68.12 USD

68.12
5,481,354

+1.62 (2.44%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $68.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.

Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates

Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.

ALC or EW: Which Is the Better Value Stock Right Now?

ALC vs. EW: Which Stock Is the Better Value Option?

DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong

DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.

Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View

Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates

Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong

West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance

Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.

CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View

CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.

Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.64% and 4.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Philips' (PHG) Q1 Earnings Jump Y/Y on Strong Top-Line Growth

Philips' (PHG) first-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More

MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.

The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI

Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences

Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.

HOLX or EW: Which Is the Better Value Stock Right Now?

HOLX vs. EW: Which Stock Is the Better Value Option?

Here's Why You Should Retain Avantor (AVTR) Stock for Now

Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.